犹他州 的 多发性骨髓瘤 临床试验
犹他州 有 21 项针对 多发性骨髓瘤 的研究正在招募参与者。
犹他州 的城市
官方研究文本（英文）
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Research Site, Salt Lake City
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月29日 · NCT07391657A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- Huntsman Cancer Institute, Salt Lake City
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年9月28日 · NCT04973605A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- Huntsman Cancer Institute, Salt Lake City
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月25日 · NCT07258511A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Utah Cancer Specialists, Salt Lake City
- Huntsman Cancer Institute, Salt Lake City
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月25日 · NCT05552222A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Utah Cancer Specialists, Salt Lake City
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月25日 · NCT07518186A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
- LDS Hospital, Salt Lake City
- Intermountain Cancer Center St. George, St. George
- St. George Regional Hospital, St. George
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月25日 · NCT05623020TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Cedar City Hospital, SW Cancer Clinic, Sandra Maxwell Cancer Center, Cedar City
- Intermountain Healthcare, Salt Lake City
- Dixie Regional Medical Center-River Road Campus, St. George
招募中2 期
12 岁及以上 · 所有性别 · 更新于 2026年9月22日 · NCT02693535A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- Huntsman Cancer Institute, Salt Lake City
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月15日 · NCT06615479A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
- Huntsman Cancer Institute /ID# 271618, Salt Lake City
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年9月14日 · NCT06953960Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- LDS Hospital, Salt Lake City
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年9月14日 · NCT06297226Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma
- Huntsman Cancer Institute at the University of Utah, Salt Lake City
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年9月11日 · NCT06517017Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma
- Huntsman Cancer Institute, Salt Lake City
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年8月28日 · NCT05344833AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
- Research Site, Salt Lake City
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年8月17日 · NCT05850234A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
- Huntsman Cancer Institute, University of Utah, Salt Lake City
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年8月12日 · NCT07280013A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
- Huntsman Cancer Institute /ID# 272575, Salt Lake City
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年7月21日 · NCT06892522Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant
- Huntsman Cancer Institute at the University of Utah, Salt Lake City
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年6月5日 · NCT05405387Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
- Huntsman Cancer Center Institute University of Utah, Salt Lake City
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年5月19日 · NCT06433947Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- University of Utah, Salt Lake City
招募中1 期
13 岁及以上 · 所有性别 · 更新于 2026年5月5日 · NCT04771572A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Huntsman Cancer Institute, Salt Lake City
- Intermountain Healthcare, Salt Lake City
招募中1/2 期
12 岁及以上 · 所有性别 · 更新于 2026年3月24日 · NCT04988555Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
- Huntsman Cancer Institute at the University of Utah, Salt Lake City
招募中观察性研究
所有年龄段 · 所有性别 · 更新于 2026年1月22日 · NCT06357754CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
- Huntsman Cancer Institute, University of Utah, Salt Lake City
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2025年9月25日 · NCT05722418数据来自 ClinicalTrials.gov，检索日期：2026年9月30日。每项研究自行设定入选标准，由研究团队决定谁能参与。